Clinical Trial: IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07799922) titled 'IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus' on Aug. 28.

Brief Summary: This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of target-immunotherapy induction and have non-progressive disease will be enrolled. All patients must be considered unresectable or unable to tolerate surgical resection by MDT review and must provide written informed consent. Participants will be randomized 2:1. Forty patients will undergo open or percutaneous IRE followed by...